Clinical Development of RAF/MEK clamp VS-6766; Breakthrough Designation & Beyond

Time: 5:00 pm
day: Day One Track I


  • RAF/MEK clamp VS-6766 and FAK inhibitor defactinib are in clinical development in RAS/MAPK driven cancers
  • Clinical experience and progress in recurrent low-grade serous ovarian cancer (LGSOC) and KRAS mutant NSCLC will be presented
  • Future directions will be discussed – including clinical trials in new indications and combination treatment approaches